Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.75 |
| ▸ | LIFR | P42702 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | FABP1 | P07148 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840444 | 0.96 | NR1H4 (0.69) | NR1H4LIFR | |
| SCHEMBL4831050 | 0.93 | NR1H4 (0.75) | NR1H4LIFR | |
| SCHEMBL4830998 | 0.92 | NR1H4 (0.72) | NR1H4LIFR | |
| SCHEMBL4427526 | 0.90 | NR1H4 (0.71) | NR1H4LIFR | |
| SCHEMBL4831063 | 0.88 | NR1H4 (0.59) | NR1H4LIFR | |
| SCHEMBL4424716 | 0.88 | NR1H4 (0.72) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4427382 | 0.88 | NR1H4 (0.69) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4429503 | 0.87 | NR1H4 (0.72) | NR1H4LIFR | |
| SCHEMBL4841116 | 0.87 | NR1H4 (0.62) | NR1H4LIFR | |
| SCHEMBL4840354 | 0.87 | NR1H4 (0.73) | NR1H4LIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | claimed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | claimed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589637-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10603320-B2 | Compounds useful for inhibiting ROR-gamma-t | ELI LILLY AND COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| EP-3347360-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018160547-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-3347360-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | Eli Lilly and Company (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017044410-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2017-03-09 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | disclosed |
| EP-1562915-A1 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004048349-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | NR1H4 24/4885LIFR 4437/4885MEN1 3433/4885 |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | NR1H4 5/4885LIFR 131/4885MEN1 4623/4885 |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | NR1H4 6/4885LIFR 316/4885MEN1 4683/4885 |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | NR1H4 5/4885LIFR 165/4885MEN1 4564/4885 |
| US-10603320-B2 | Compounds useful for inhibiting ROR-gamma-t | RORC, RORB, RORA | NR1H4 7/4885LIFR 199/4885MEN1 4517/4885 |
| US-20060258725-A1 | Farnesoid x receptor agonists | NR1H4, GPBAR1, NR1H2 | NR1H4 1/4885LIFR 2155/4885MEN1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.